NAMS

NewAmsterdam Pharma Company N.V.

9.05 USD

Last updated Dec 9, 04:20 UTC

Yesterday HIGH

$9.64

Yesterday LOW

$8.95

52w HIGH

$18.7

52w LOW

$5.63

EPS

1

PE

9.05

Overview News Government Trades

NewAmsterdam Pharma Company N.V. stock is down -6.89% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.

No data available.

Stock Exchange

-

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Narrden, Netherlands

Website

newamsterdampharma.com

Lisa Levin

Tue Jan 31, 2023

Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers
Benzinga Insights

Tue Jan 31, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Lisa Levin

Tue Jan 31, 2023

US Stocks Mixed; McDonald's Earnings Top Estimates

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 30 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.09% to 33,685.72 while the NASDAQ rose 0.29% to 11,426.75. The S&P 500 also rose, gaining, 0.15% to 4,023.77.
Lisa Levin

Fri Jan 27, 2023

Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers FOXO Technologies Inc. (NYSE: FOXO) shares jumped 109% to $1.07. Akanda Corp. (NASDAQ: AKAN) rose 59% to $0.4459 after jumping 47% on Thursday.
Benzinga Insights

Fri Jan 27, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Lisa Levin

Fri Jan 27, 2023

Top 5 Health Care Stocks That May Dip

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Vandana Singh

Tue Jan 17, 2023

Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment
Benzinga Newsdesk

Tue Jan 17, 2023

NewAmsterdam Announces ROSE2 Phase 2 Trial Evaluating Obicetrapib In Combination With Ezetimibe Achieved Primary Endpoint
Benzinga Insights

Fri Jan 6, 2023

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Benzinga Newsdesk

Fri Jan 6, 2023

Credit Suisse Initiates Coverage On NewAmsterdam Pharma with Outperform Rating, Announces Price Target of $21

Credit Suisse analyst Judah Frommer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating and announces Price Target of $21.

CRSP $64.52 USD

UPST $37.01 USD

VRTX $350.22 USD

PARA $16.84 USD

HDSN $12.99 USD

SAVA $24.36 USD

WRBY $10.66 USD